Comprehensive Study Notes on Cancer Cell Biology: Alkylating Agents and Antimetabolites
Introduction to Cancer Pathophysiology and Carcinogenesis
Cancer is defined as a disease characterized by the uncontrolled multiplication and spread of abnormal forms of the body's own cells. It is primarily considered a disease of cell proliferation, where cells divide and reproduce at dysregulated rates. A normal cell undergoes transformation into a cancer cell due to one or more mutations in its DNA, which may be acquired through environmental exposure or inherited through genetic lineage. These transformed cells exhibit growth that is no longer subject to normal regulatory controls. Because they proliferate rapidly, cancer cells compete with normal cells for limited energy and nutritional resources, which ultimately results in the deterioration of normal organ function. Furthermore, the growth of cancerous masses can impinge on vital organs through mass effects. If genetic changes are not repaired, mutated genes—specifically those involved in growth regulation and DNA repair—can express altered gene products that facilitate further abnormal cell growth and proliferation.
Carcinogenesis, the process by which cancer develops, occurs in main steps: transformation, proliferation, and metastasis. Transformation denotes the phenotypic change from a cell with normal growth controls to one with dysregulated growth. These nonlethal genetic changes or mutations can be inherited, occur spontaneously, or be induced by environmental agents such as chemicals, radiation, or viruses. Proliferation is the second step, representing the growth of transformed cells into a tumor through a significant increase in the total number of cells. Metastasis, the third step, involves the formation of secondary tumors. These occur when cells are released from the initial or primary tumor and reach distant sites through blood vessels, lymphatics, or by being shed into body cavities. Metastases are the principal causes of morbidity and mortality in most cancer cases and represent a major challenge for effective cancer therapy.
Classification of Drugs Used in Cancer Chemotherapy
Anticancer drugs are categorized into several general groups based on their mechanism of action and origin. Cytotoxic drugs include alkylating agents and related compounds, such as Cyclophosphomide, Chlorambucil, Busulfan, Chlormetin, Cisplatine, and Melphalan, which act by forming covalent bonds with DNA to impede replication. Another major cytotoxic group is the antimetabolites, including Methotrexate, Fluorouracil, Cytarabine, and mercaptopurine, which block or subvert metabolic pathways involved in DNA synthesis. Cytotoxic antibiotics are substances of microbial origin, such as doxorubicin, idarubicin, and mitoxantrone, that prevent mammalian cell division.
Natural products, also known as mitotic inhibitors, are derived from plants and include vinca alkaloids like vincristine, vinblastine, and vindesine, as well as taxanes and campothecins. Most of these drugs specifically affect microtubule function and the formation of the mitotic spindle. Hormonal therapy involves the use of steroids, such as the glucocorticoids prednisolone and dexamethasone, as well as estrogens and androgens. This category also includes drugs that suppress hormone secretion or antagonize hormone action. Finally, there is a miscellaneous group of drugs that do not fit into the aforementioned categories.
General Principles and Mechanisms of Alkylating Agents
Alkylating agents are compounds that react with electron-rich atoms in biological molecules to form covalent bonds. These highly reactive drugs bind to specific chemical groups commonly found in nucleic acids and other macromolecules, including phosphate, amino, sulfhydryl, hydroxyl, and imidazole groups. By substituting alkyl groups for hydrogen atoms on DNA, these agents cause the formation of cross-links within the DNA chain. These alterations result in cytotoxic, mutagenic, and carcinogenic effects. While this action occurs across all cells, the primary impact is on rapidly dividing cells because they lack the necessary time for DNA repair before replication. Because cancer cells are among the most rapidly dividing, they are among the most affected. However, other rapidly dividing cells, such as hematopoietic, reproductive, and endothelial cells, are also affected, leading to common side effects like anemia, pancytopenia, amenorrhea, impaired spermatogenesis, intestinal mucosal damage, alopecia, and an increased risk of secondary malignancy.
The alkylation process leads to the misreading of the DNA code and the inhibition of DNA, RNA, and protein synthesis. This ultimately triggers programmed cell death, or apoptosis, in rapidly proliferating tumor cells. Most cytotoxic anticancer alkylating agents are bifunctional, meaning they possess alkylating groups. The primary molecular target for alkylation in DNA is the nitrogen at position () of guanine, which is strongly nucleophilic. Other targets include the and positions of adenine and the position of cytosine. Bifunctional agents can react with separate groups to cause intra-chain or inter-chain cross-linking in the DNA. This interferes with both transcription and replication, the latter being the critical effect for anticancer activity. The result is that the nucleic acid cannot be replicated, leading either to cell death (cytotoxicity) or changes in cell characteristics (mutagenicity), which may eventually lead to further carcinogenicity.
Specific Classes and Profiles of Alkylating Agents
Alkylating agents are generally separated into distinct classes. The nitrogen mustards include mechlorethamine, cyclophosphamide, ifosfamide, melphalan, and chlorambucil. Ethylenamine and methylenamine derivatives include altretamine and thiotepa. Alkyl sulfonates are represented by busulfan. Nitrosoureas include carmustine and lomustine. Triazenes consist of dacarbazine, procarbazine, and temozolomide. Finally, platinum coordination complexes include cisplatin, carboplatin, and oxaliplatin. Although these platinum agents do not alkylate DNA in the traditional sense, they are classified as alkylating agents because they produce covalent DNA adducts. Alkylating agents are frequently used in combination with other drugs to treat lymphoma, leukemia, testicular cancer, melanoma, brain cancer, and breast cancer. Generic unwanted effects include severe nausea, vomiting, and a decrease in red and white blood cell counts.
Chlorambucil exhibits rapid gastrointestinal absorption, though food can decrease this, and it is excreted in the urine. It is indicated for Chronic Lymphocytic Leukemia and Hodgkin or Non-Hodgkin lymphoma. Adverse effects include myelosuppression, immunosuppression, nausea, vomiting, hepatotoxicity, malignancy, infertility, and teratogenicity. Cyclophosphamide also shows good oral absorption and urinary excretion. It is used for Hodgkin and Non-Hodgkin lymphoma, multiple myeloma, breast and ovarian cancer, neuroblastoma, and retinoblastoma. Its adverse effects are similar to chlorambucil but include cardiotoxicity, renal toxicity, and alopecia.
Ethylenimines such as Thiotepa and Altretamine form DNA cross-links via alkylation, primarily at the position of guanine, inhibiting DNA synthesis. They can be administered intravenously or intrathecally and are excreted in the urine. They are indicated for beta thalassemia and carry risks of myelosuppression, CNS toxicity (headache, confusion, encephalopathy), dermatologic toxicity (pruritus, blistering), and hepatic sinusoidal obstruction syndrome. Busulfan, an alkyl sulfonate, is used for Chronic Myeloid Leukemia. It is rapidly absorbed, crosses the blood-brain barrier, and is excreted in urine. Side effects include hyperpigmentation, adrenal insufficiency, and lung issues like cough and dyspnea.
Nitrosoureas like Carmustine and Lomustine are highly lipid-soluble, allowing them to cross the blood-brain barrier to treat CNS malignancies. They alkylate the and positions of guanine to prevent replication and transcription. Carmustine is given intravenously and used for brain tumors and multiple myeloma. Side effects include arrhythmia, tachycardia, mucositis, and interstitial pneumonitis. Triazines such as Procarbazine and Dacarbazine also inhibit DNA synthesis through alkylation. Procarbazine is indicated for Hodgkin Lymphoma and can cause CNS toxicity, hemolysis, and hemorrhage. Platinum coordination complexes like Cisplatin covalently bind DNA to form cross-links. Cisplatin is used for bladder, ovarian, and testicular cancers. Its specific adverse effects include peripheral neuropathy, nephrotoxicity, and ototoxicity.
General Principles of Antimetabolites
Antimetabolites are drugs that interfere with the synthesis of essential cellular components such as DNA, RNA, and coenzymes by mimicking or blocking naturally occurring metabolites. They are classified into main categories: folic acid analogues, purine analogues, and pyrimidine analogues. These drugs are most effective against cancer cells because those cells spend more time dividing than normal cells, making inhibiting cell division more harmful to the tumor. Antimetabolites are commonly used for leukemia and cancers of the breast, ovary, and gastrointestinal tract. They function by either incorporating chemically altered nucleotides into DNA or by depleting the supply of deoxynucleotides required for replication. Many antimetabolites are structural analogues of endogenous molecules or folate cofactors.
These drugs often masquerade as purines or pyrimidines, the building blocks of DNA, and prevent their incorporation during the S phase of the cell cycle. This stops normal development and cell division. While they can affect RNA, some drugs like those inhibiting thymidylate synthase selectively target DNA synthesis because thymidine is found in DNA but not in RNA. Due to their efficiency, antimetabolites are the most widely used cytostatics. They compete for binding sites on enzymes and trigger apoptosis upon incorporation into nucleic acids. Most have high cell cycle specificity and can target the arrest of cancer cell DNA replication.
Specific Profiles of Antimetabolite Drugs
Methotrexate is a folic acid antagonist that inhibits dihydrofolate reductase (DHFR). This enzyme is responsible for converting folic acid to its active reduced form, folate, which is a required step for DNA synthesis. Methotrexate causes a build-up of inactive folates. Its toxicities include myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, and neurotoxicity. To prevent nephrotoxicity, patients should maintain hydration and alkalinize the urine to a pH > 7. Methotrexate can interact with weak acids like NSAIDs and penicillin compounds, which may cause the drug to precipitate.
6-mercaptopurine (6-MP) is a purine analogue and an active metabolite of the prodrug azathioprine. It substitutes for natural purine bases in DNA, leading to miscoding and impaired replication. It is primarily indicated for acute lymphoid leukaemia (ALL). Side effects include myelosuppression, mucositis, and hepatotoxicity. Importantly, the co-administration of allopurinol can increase the concentration of 6-MP, potentially leading to increased toxicity.
5-Fluorouracil (5-FU) is a pyrimidine analogue that inhibits thymidylate synthase, the rate-limiting enzyme for thymidine generation. It is metabolized into 5-fluorouracil triphosphate and incorporated into RNA. It is used for colon, pancreatic, head and neck cancers, and hematological malignancies. Toxicity varies by administration: bolus infusions are linked to myelosuppression, while continuous infusions lead to diarrhea and hand-foot syndrome. Folinic acid (leucovorin) is administered with 5-FU to increase the stability of its binding to thymidylate synthase, enhancing its efficacy and allowing for lower doses. However, leucovorin is not used as a rescue medication for 5-FU as it is for methotrexate.
Cytarabine is another pyrimidine analogue and a prodrug for ara-cytosine triphosphate. This metabolite blocks DNA polymerase processivity during replication and induces RNA miscoding. It is effective for leukaemias and lymphomas. Common adverse effects include myelosuppression, nausea, vomiting, cerebellar toxicity (neurological symptoms), and conjunctivitis. General side effects across the antimetabolite class also include loss of appetite, tiredness, weakness, dizziness, headache, mouth inflammation, elevated liver enzymes, hair loss, and bowel changes such as diarrhea or constipation.